Ratings by UBS (Andrew Ang)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/18/2024 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/27/2024 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/28/2023 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/31/2023 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 5/17/2022 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 1/21/2022 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/29/2021 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/27/2021 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 12/4/2020 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/12/2020 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 1/22/2020 | BioNTech | BNTX | Downgrade | Neutral (Buy) |
33.18 (101.50) |
205.91% | Details | |
| 11/4/2019 | BioNTech | BNTX | New Coverage | Buy (N/A) |
16.82 (101.50) |
503.45% | Details | |
| 9/17/2019 | Alder Biopharm | ALDR | Upgrade | Neutral (Sell) |
10.06 (18.88) |
87.67% | Details |
